Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LINC01744 (Long intergenic non-protein coding RNA 1744) is a member of the lincRNA class, which are autonomously transcribed RNAs longer than 200 nucleotides that do not overlap annotated protein-coding genes[1][3][5]. LINC01744 itself is catalogued in genomic databases, but to date, little is known about its specific biological role. LincRNAs as a class remodel chromatin, govern transcriptional programs, and participate in regulating the activity of chromatin modifiers and transcription factors, often with tissue-specific and context-dependent functions[3][5][7]. While many lincRNAs have demonstrated importance in gene regulation or disease mechanisms, there is no published evidence (as of mid-2024) establishing LINC01744 as a therapeutic target or functional biomarker, nor describing its molecular partners, drugs, or involvement in disease mechanisms[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1744 (LINC01744).